RxDoctor Payments Data

Rene Desmarais, MD

Cardiovascular Disease · Salisbury, MDNPI 1518942390

Payments from drug & device makers

$2,202in general payments, 2019–2025

Across 123 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$666
  • E.r. Squibb & Sons, L.L.C.$283
  • AstraZeneca$210
  • Johnson & Johnson$200
  • Boehringer Ingelheim$156
  • Amgen$151
  • plus $536 from 10 others

What the payments were for

  • Food & beverage$2,14597%
  • Education$573%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,202 in reported general payments places this provider in the 50th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$948,837
Medicare patients
1,957
Services billed
9,758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban303$343,436
XareltoRivaroxaban188$218,756
EntrestoSacubitril/Valsartan69$84,607
BrilintaTicagrelor42$40,204
Repatha SureclickEvolocumab25$24,079
MultaqDronedarone Hcl18$23,363
FarxigaDapagliflozin Propanediol14$21,634
JardianceEmpagliflozin12$15,976
Metoprolol Succinate407$8,760
Atorvastatin Calcium380$4,857
Metoprolol Tartrate490$4,493
Isosorbide Mononitrate ErIsosorbide Mononitrate180$3,748
Potassium Chloride153$3,481
Prasugrel Hcl20$3,410
Carvedilol300$3,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$84$343,436303 claims
Johnson & JohnsonXarelto$200$218,756188 claims
NovartisEntresto$117$84,60769 claims
AstraZenecaBrilinta, Farxiga$210$61,83956 claims
Boehringer IngelheimJardiance, Pradaxa$156$18,40723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →